The Consulate General India - Chicago organized a Life Science Summit on May 18, 2015 at Chicago Mr. Dinesh Jain, Founder CEO, Aagami Inc. and Mr. Michael Rosen, Managing Director, Rosen Bioscience Strategies (also partner consultant at Aagami) attended the event as speakers and made a presentation on “Life Science Connections between the Midwest and India” as well as some of the life science M&A and FDI activity going on between the U.S. and India”

1. Realizing Possibilities, Together
Aagami , Inc. | 2135 City Gate Lane, Suite 300, Naperville, IL 60653 USA | P: +1-630-364-1837 | www.aagami.com
CROSS-BORDER LIFESCIENCES DEALS (2013-2015):
A Perspective
© Aagami, Inc. 2015 | All rights reserved | www.aagami.com
Dinesh Jain| Michael Rosen

2. © Aagami, Inc. 2015 | All rights reserved | www.aagami.com 2
Table of Contents
Overall Pharma Market Trends
M&A
Joint Ventures/Co-Development
Licensing
Aagami Profile
CROSS BORDER LIFESCIENCES DEALS - US & INDIA (2013-2015)
Note : These are some of the deals which Aagami Market Research Team have sourced
from Publicly available data and hence not exhaustive

3. © Aagami, Inc. 2015 | All rights reserved | www.aagami.com 3
• Indian Pharma Market = ~ $22 B; projected to
grow to $55 B by 2020 (McKinsey)
• India pharma exports $15.2 B in pharmaceutical
products ($4.2B to US)
• 584 FDA –approved pharma manufacturing
facilities
• >3,000 pharma companies
• Bi-national M&A (2013-2015)*
 U.S. pharma spent more than $2.7 B to acquire Indian
pharma
 Indian pharma spent $180 M to acquire U.S. biotech
and >$180 M in FDI
* Counting only deal amounts which were publicly disclosed

4. © Aagami, Inc. 2015 | All rights reserved | www.aagami.com 4
Indian Co. US Co.
Deal Size - M Year Remarks
Aurobindo Natrol Inc. $132.5 2014 Nutraceuticals platform for US & ROW
Piramal
Coldstream
Laboratories
$30.65 2015 Injectable market segment
SRF
Dupont $ 20 .0 2015 Pharma propellant business
Sun Pharma Pharmalucence N/A 2014 Radio- pharmaceuticals and US injectable business
Kemwell
Cirrus N/A 2013 Products with faster time-to-clinic and cost savings for
customers

5. © Aagami, Inc. 2015 | All rights reserved | www.aagami.com 5
US Co. Indian Co. Deal Size - M Year Remarks
Mylan Agila $1,600 2013 Become top-three global player in injectables
Mylan Famy Care $800 2015 Global women's health care
Hospira
Orchid
Pharma
$200 2014 API supplier for key antibiotics and future API development.
Carlyle
Group
Bharat
Serum $83 2014 25-30% stake from existing investors.
Amneal
Pharma
Epsilon
Pharma
$16 2014
Expand footprint in India. Includes 200,000 + sf. US FDA
certified manufacturing facility.
Quantum
solutions
Parexel N/A 2015
Create greater scale in service area, and provide
comprehensive and efficient solution to global clients.

6. © Aagami, Inc. 2015 | All rights reserved | www.aagami.com 6
Indian Co. US Co. Year Remarks
Ami Organics Photolitec 2015
Clinical trials to determine cancer treatments safety and
and efficacy.
Emami
Hevert-
Arzneimittel
2014
Launched products via 400 homoeopathy medicine retail
outlets across diverse distribution channels via Emami.
Agila Biotech Pfenex Inc 2013
Develop, manufacture and commercialize initial pipeline of
6 biosimilar products. AB = 51% equity stakeholder

7. © Aagami, Inc. 2015 | All rights reserved | www.aagami.com 7
Indian Co. US Co. Year Remarks
Ipca
Labs
Oncobiologics 2014
Development, manufacture and commercialization of biosimilar monoclonal
antibodies.
Cipla BioQuiddity 2014
Commercial collaboration on OneDose ReadyfusOR™ in anaesthetic applications
for post-surgical pain management.
GVK Bio Endo Pharma 2013
Novel small molecules. GVK BIO will use discovery expertise and Endo will
develop/commercialize product.
Advinus
Moffitt Cancer
Centre
2013 New oncology therapies.
GVK Bio
Onconova
Therapeutics
2013
US JV to move Onconova oncology assets from early discovery to clinical
development stage.
Cadila Novavax 2013 Extension to JV in 2009 collaboration to develop novel malaria vaccine in India.

8. © Aagami, Inc. 2015 | All rights reserved | www.aagami.com 8
Indian Co. US Co. Deal Size - M Year Remarks
Lupin US Market $177.5 2014
2 new US R&D Centres on inhalation and complex formulations
research.
Glenmark US Market $100 2014 Greenfield facility for US market.
Cipla Chase Pharma $6.0 2014
Alzheimer’s drug development. Part of $21 M investment
through syndicate.
Strides
Arcolabs
Oncobiologics N/A 2014 Strategic stake.
Indian Co. US Co. Deal Size - M Year Remarks
Laurus Lab Warburg Pincus $92 2014 Create durable businesses of scale with sustainable value.
Ashland
Investment in
India
$ 10 2014 2 centres of excellence — new pharma in Hyderabad and
existing personal care in Mumbai

9. © Aagami, Inc. 2015 | All rights reserved | www.aagami.com 9
Indian Co. US Co. Year Remarks
Sun Pharma Merck 2014 Worldwide rights to tildrakizumab. $ 280 M Deal
MedGenome Natera 2015 Exclusive license to develop Natera's Panorama.
Strides
Arcolabs
Gilead 2015 Non-exclusive rights to manufacture and distribute Tenofovir Alafenamide (TAF); license
extends to 112 countries
Natco India Gilead 2015 Generic versions of chronic hepatitis C medicines.
Ranbaxy Epirus 2014 Infliximab (arthritis) with annual sales of $6 billion..
Biocon Cytosorbents
Corporation
2014 Distribute CytoSorb® for critical care applications in ICU and cardiac surgery applications
for India and select emerging countries.
Indian Co. US Co. Year Remarks
Caplin Point Fresenius
Kabi
2015 Parenteral products; Fresenius Kabi will hold ANDAs and commercialise in USA.

10. © Aagami, Inc. 2015 | All rights reserved | www.aagami.com
10
Aagami, Inc.
Life Sciences consulting firm based in
Chicago suburbs offers:
For Global Biotech, Pharmaceutical , Medical Devices and Consumer
Health products companies.
Strategic Consulting Services
Technology Licensing Services
Business & Market Research Services

11. © Aagami, Inc. 2015 | All rights reserved | www.aagami.com
11
Strategic Consulting Services
 In-Licensing/Out-Licensing
 Co-Development & Partnerships
 Investments to/from US, India, Asia, Latin America
 Mergers & Acquisitions
 Finding the Right Partners
 JV and/or Distributors
 CRO/CRAMS providers
 Contract Sales/Marketing
 Contract Manufacturing

12. 12
Aagami Clients
International
Phosphagenics Australia
PeptiSyntha Belgium
DelMar Pharma Canada
Affitech Denmark
Pieris Germany
Merus Holland
Venus Remedies India
Opsona Ireland
Toppan Japan
Otago University New Zealand
Aagami has completed over 100 assignments for more than 50 clients in the last 11+ years.
United States
Advangene IL
Loyola Univ. Chicago IL
Dow Chemicals MI
ScyFIX MN
OncBioMune LA
Penwest Corp. NY
DesignMedix OR
PLx TX
CreAgri CA
New Heaven Pharma CT

13. 13
Aagami Connectivity in India
We are connected at CXO Level of TOP 100 Lifesciences companies
in India including:
Biocon Intas Sun Pharma
Cadila Lupin Themis
Cipla MicroLabs Torrent Pharma
Dr Reddys Piramal USV
Glenmark Reliance Wockhardt
Hetero Drugs Strides Zydus

14. © Aagami, Inc. 2015 | All rights reserved | www.aagami.com
USA (Head Office)
Aagami, Inc.
2135 City Gate Lane Suite 300
Naperville, IL 60653
P: +1-630-364-1837
INDIA
Aagami
741, Nelson Square
Nagpur – 440013
P: +91-712-258-6678
Dinesh Jain
Email: dinesh@aagami.com
M: +1 630-853-3520
Godwyn Francis
Email: godwyn@aagami.com
M: +91-787-501-6957
www.aagami.com
14
Realizing Possibilities, Together